Aligos Therapeutics, Inc. ALGS 深 沪
等待开盘 03-26 09:30:00 美东时间
6.87
+0.080
+1.18%
华盛通- 最 高7.3775
- 今 开6.94
- 成交量 1.95万股
- 最 低 6.84
- 昨 收 6.79
- 总市值 4251.02万
- 52周最高 13.6892
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 3.76
- 委 比 50.75%
- 总股本 618.78万
- 历史最高 937.75
- 量 比 0.64
- 振 幅 7.92%
- 历史最低 3.76
- 每 手 1
- 风险率 1.84%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
Jefferies Assumes Aligos Therapeutics at Buy, Lowers Price Target of $48
Jefferies analyst Anthea Li assumes Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and lowers Price Target of $48.
03-20 03:40
美股大行评级 | 甲骨文绩后分歧大！小摩上调评级至"超配"，目标价缺降至210美元；科尔士百货、AVAV、Blend Labs、Domo遭多家大行下调评级
今日重点评级关注：LUCID CAPITAL MARKETS：上调INmune Bio评级至"买入" 目标价从2美元升至9美元；Clear Street：维持MoonLake Immunotherapeutics Class A"买入"评级，目标价从45美元升至70美元
03-12 12:34
HC Wainwright & Co. Reiterates Buy on Aligos Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Aligos Therapeutics (NASDAQ:ALGS) with a Buy and maintains $50 price target.
03-12 01:19
Aligos Therapeutics Earnings Report: Q4 Overview
The Q4 earnings report for Aligos Therapeutics (NASDAQ:ALGS) was released on Th...
03-05 21:14
Aligos Therapeutics Q4 EPS $(1.91) Beats $(2.27) Estimate, Sales $169.000K Miss $800.000K Estimate.
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(1.91) per share which beat the analyst consensus estimate of $(2.27) by 15.67 percent. This is a 85.4 percent increase over losses of $(13.08) per share
03-05 21:12
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
美股大行评级 | 瑞银上调美光科技目标价从300美元升至400美元；Freedom上调百度目标价从120美元升至160美元
今日重点评级关注：Needham：维持Vaxcyte"买入"评级，目标价从90美元升至110美元；Citizens: 维持LGI Homes"跑赢大市"评级，目标价从85美元升至95美元
01-08 18:33
UBS Initiates Coverage On Aligos Therapeutics with Buy Rating, Announces Price Target of $20
UBS analyst Michael Yee initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Buy rating and announces Price Target of $20.
01-08 04:13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
